INTRODUCTION
Serum tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen are commonly used in colorectal cancer (CRC) clinics. However, their clinical usefulness remains controversial from diagnostic, prognostic, and surveillance points of view [1] .
The American Society of Clinical Oncology guidelines suggest that there is insufficient evidence for using CA 19-9 in the management of patients with CRC [2] . This study was designed to elucidate the efficiency of preoperative serum levels of CA 19-9 (pre-CA 19-9) as a tool thesurgery.or.kr 
DISCUSSION
CA 19-9 is a predominant carbohydrate antigen that was defined from the culture medium of a CRC cell line [3] . Serum CEA and CA 19-9 are commonly used as classical tumor markers in CRC patients [4] . But Yamashita and
Watanabe [1] suggested that pre-CEA and pre-CA 19-9 do not show satisfactory sensitivity as screening (diagnostic) markers in CRC. The utility of CA 19-9 as a diagnostic marker in colorectal cancer is limited in a number of ways.
First, patients with negative Lewis blood group antigen cannot synthesize CA 19-9, and therefore it is not used as a serologic marker in these individuals, who make up about 10% of the population. Second, patients with benign biliary tract disease can have levels up to 400 U/mL, with 87%
having concentrations higher than 70 U/mL. Significant numbers of patients with pancreatitis, either acute or chronic, also have elevated levels. Third, besides pancreatic cancer, CA 19-9 levels are also elevated in patients with other cancers, including those of the biliary tree (95%), stomach (5%), liver (hepatocellular carcinoma, 7%), and lung (13%). For CRC, CA 19-9 levels add little clinically useful information to determine CEA levels [5] . The low diagnostic power of CA 19-9 may be due to a high proportion of colorectal cancer patients having the Lewis (a-b-) phenotype, who cannot synthesize these markers [6] . The overall reported incidences of high pre-CA 19-9 range from 10.6% to 24.4% [7] [8] [9] [10] [11] . In our study, there were 61 patients (18.3%) with high pre-CA 19-9 among 333 patients. The American Society for Clinical Oncology recommends that the present data are insufficient to recommend CA 19-9 for screening, diagnosis, staging, surveillance, or monitoring treatment of patients with CRC [12] .
Nevertheless, the clinical significance of pre-CA 19-9 is still controversial. Morita et al. [13] did not recommend routine use of CA 19-9 in staging and surveillance of CRC, because they could not find clinical significance to support the use of pre-CA 19-9 to predict the prognosis and detect recurrence of CRC [13] . In contrast, Nakagoe et al. [7] advocated that high pre-CA 19-9 may serve as a useful marker in identifying patients with node-negative CRC at high risk for recurrence after surgery [7] . The discrepancy is considered to be derived from the difference in size of the study and distribution of tumor stage in each study population. In another multivariate analysis showed tumor progression on chemotherapy (P ＜ 0.0001), elevated preoperative serum CA 19-9 (P ＜ 0.0001), number of resected metastases (P ＜ 0.001), and the number of lines of chemotherapy (P ＜ 0.04), but not the type of first line treatment, were independently associated with decreased survival [14] . We have concentrated on the significance of pre-CA 19-9 for CRC staging. In this study, high pre-CA 19-9 was shown to be independently associated with high pre-CEA, lymph node metastasis, right colon cancer, large tumor size, and peritoneal seeding.
It was interesting to find that high pre-CA 19-9 level was a predictive marker of peritoneal seeding before surgery.
This kind of correlation between CA 19-9 and peritoneal seeding has been reported by some authors. Liu et al. [15] reported that depth of bowel wall invasion, lymph node metastasis, serum CEA level, and CA 19-9 level are risk factors for peritoneal metastasis in colorectal cancer. Yang et al. [10] suggested that CA 19-9 (＞34.6 U/mL), pT4 and age (＜59 years) were significant risk factors of positive peritoneal dissemination. Park et al. [8] reported postoperative serum CA 19-9 elevation was better related to peritoneal recurrence than to liver metastasis. Especially, Yang et al. [10] Lewis showed a lower expression in Dukes' A and B tumors than in more advanced stages [17] . These structures are of increasing interest since they may function as adhesion molecules; adhesion of tumor cells to the endothelial cell of blood vessels may be mediated by an interaction between sialyl Lewis and E-selectin [18] and tumor cell induced platelet aggregation [19] . Therefore, it was thought thesurgery.or.kr that the mechanism associated with colorectal cancer expressing pre-CA 19-9 might have a higher possibility of peritoneal seeding. High pre-CA 19-9 might be associated with advanced colorectal cancer including peritoneal recurrence and lung metastasis. Lin et al. [9] reported that CA 19-9 may be a prognostic factor for CRC patients with normal CEA levels and an aggressive follow-up protocol for lung metastasis should be used for these patients.
But this study had limitations in its results because the incidences of high pre-CA 19-9 were low (18.3%). Therefore, to make up for low incidence of pre-CA 19-9, the com- 
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was reported.
